Evidence map›Paper›PMID 31109071›Full record

ReviewInternational journal of molecular sciences2019

Metabolomics of Type 1 and Type 2 Diabetes.

Borros Arneth, Rebekka Arneth, Mohamed Shams

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Metabolomics in Diabetic Retinopathy: A Systematic Review.Investigative ophthalmology & visual science · 2021
    Pooled it
  6. Pooled it
  7. Trial
  8. Protein phosphatase 2A impairs cardiac uptake of glucose in the mammalian heart.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Comparison of Islet Function in People With Different Glucose Metabolic States.Endocrine, metabolic & immune disorders drug targets · 2026
    Article
  15. Article
  16. Leaf Ethanol Extract ofBiochemistry research international · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Review

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Borros ArnethInstitute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Hospital of the Universities of Giessen and Marburg (UKGM), Justus Liebig University Giessen, Feulgenstr. 12, 35392 Giessen, Germany. borros.arneth@klinchemie.med.uni-giessen.de.
Rebekka ArnethClinics for Internal Medicine 2, University Hospital of the Universities of Giessen and Marburg UKGM, Justus Liebig University. Giessen, 35392 Giessen, Germany. Rebekka.R.Arneth@innere.med.uni-giessen.de.
Mohamed ShamsDepartment of Pharmacy Practice, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. mshamspharma@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 and type 2 diabetes mellitus (DM) are chronic diseases that affect nearly 425 million people worldwide, leading to poor health outcomes and high health care costs. High-throughput metabolomics screening can provide vital insight into the pathophysiological pathways of DM and help in managing its effects. The primary aim of this study was to contribute to the understanding and management of DM by providing reliable evidence of the relationships between metabolites and type 1 diabetes (T1D) and metabolites and type 2 diabetes (T2D). Information for the study was obtained from the PubMed, MEDLINE, and EMBASE databases, and leads to additional articles that were obtained from the reference lists of the studies examined. The results from the selected studies were used to assess the relationships between diabetes (T1D and/or T2D) and metabolite markers-such as glutamine, glycine, and aromatic amino acids-in patients. Seventy studies were selected from the three databases and from the reference lists in the records retrieved. All studies explored associations between various metabolites and T1D or T2D. This review identified several plasma metabolites associated with T2D prediabetes and/or T1D and/or T2D in humans. The evidence shows that metabolites such as glucose, fructose, amino acids, and lipids are typically altered in individuals with T1D and T2D. These metabolites exhibit significant predictive associations with T2D prediabetes, T1D, and/or T2D. The current review suggests that changes in plasma metabolites can be identified by metabolomic techniques and used to identify and analyze T1D and T2D biomarkers. The results of the metabolomic studies can be used to help create effective interventions for managing these diseases.

Indexed as

BiomarkersMetabolomeMetabolomicsAmino AcidsAnimalsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansHypoglycemic AgentsInsulin ResistanceAmino AcidsBiomarkersHypoglycemic Agentsbiomarkersdiabetes mellitus type 1diabetes mellitus type 2metabolism

Identifiers

PMID31109071
PMCPMC6566263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.